SU2C scientists probe patient response to cancer immunotherapy - Stand Up To Cancer

Give Now

News

SU2C scientists probe patient response to cancer immunotherapy

In research supported by SU2C, F. Stephen Hodi, MD, of the Dana-Farber Cancer Institute and colleagues investigated whether a serumbiomarker could predict the response of patients receiving immune checkpoint inhibitors, a type of immunotherapy. This is very important to improving the utilization ofimmunotherapies. According to a paper published in a journal published by SU2C’s Scientific Partner, the American Association for Cancer Research, Hodi’s team found that serum levels of a protein called ANGPT2 predicted response to, and influenced the outcomes of,immune checkpoint inhibitors in patients with advanced melanoma.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.